544 DELTA-1: A global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma

• Omid Hamid,
• Robert Hawkins,
• Paul Robbins,
• Gregory Daniels,
• Geoffrey Gibney,
• Amod Sarnaik,
• Brian Gastman,
• Bartosz Chmielowski,
• Evidio Domingo-Musibay,
• Sajeve Thomas,
• Pippa Corrie,
• Donald Lawrence,
• Yizhou Jiang,
• Rubén Alvarez-Rodríguez,
• Audrey Kennedy,
• Jeff Aycock,
• John Le Gall,
• Zachary Roberts

Affiliations

Omid Hamid

Cedars-Sinai Medical Center Angeles Clinic and Research Institute, Santa Monica, California, USA

Robert Hawkins

Aff1 grid.412917.80000000404309259Department of Medical OncologyChristie NHS Foundation Trust Manchester United Kingdom

Paul Robbins

Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA

Gregory Daniels

3University of California, La Jolla, CA, USA

Geoffrey Gibney

8Georgetown University, Washington, DC, USA

Amod Sarnaik

1H. Lee Moffitt Cancer Center, Tampa, FL, USA

Brian Gastman

Department of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA

Bartosz Chmielowski

Aff10 grid.19006.3e0000000096326718Division of Hematology - Medical OncologyUCLA Jonsson Comprehensive Cancer Center Los Angeles CA USA

Evidio Domingo-Musibay

5University of Minnesota Medical Center, Minneapolis, MN, USA

Sajeve Thomas

MD Anderson Cancer Center Orlando, Orlando, Florida, USA

Pippa Corrie

Department of Oncology, Addenbrooke`s Hospital, Cambridge, UK

Donald Lawrence

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA

Yizhou Jiang

2Instil Bio, Inc., Dallas, TX, USA

Rubén Alvarez-Rodríguez

Instil Bio, Inc., Dallas, TX, USA

Audrey Kennedy

11Instil Bio, Inc, Dallas, TX, USA

Jeff Aycock

10Instil Bio, Inc., Dallas, TX, USA

John Le Gall

10Instil Bio, Inc., Dallas, TX, USA

Zachary Roberts

10Instil Bio, Inc., Dallas, TX, USA